Experimental MDS drug trial halted after just 2 patients
NCT ID NCT05148234
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called BMS-986253, alone or with standard chemotherapy, for people with myelodysplastic syndromes (MDS), a group of bone marrow disorders. The study aimed to find a safe dose and see if the drug could shrink cancer. However, the trial was terminated early after enrolling only 2 participants, so no conclusions about safety or effectiveness can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BMS-986253 (an antibody targeting interleukin-8), given alone or with decitabine and cedazuridine
- What this could lead to
- If it works, this could point toward a new treatment option for myelodysplastic syndromes, especially for people who don't respond well to current therapies.
- What could go wrong
- This was a very early, small trial (only 2 participants enrolled) that was terminated, so we don't have enough data to know if it's safe or effective. Many early-stage drugs fail to show benefit in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a new drug offer hope for blood cancers when chemo fails?
- Can a Gene-Targeted pill turn the tide against a rare blood cancer?